Post AACR Blog #2: Cancer Immunotherapy

The ability to mobilize the immune system to fight cancer has revolutionized the way we treat this disease. It’s no surprise that Cancer Immunotherapy was a prominent topic at the 2017 American Association for Cancer Research (AACR) annual meeting. Despite the successes associated with immunotherapy there are still many questions to be answered. Investigators at AACR provided a nice framework for future research by posing both big picture and mechanistic questions. Why does immunotherapy work only for a small percentage of patients? What are the mechanisms of cancer resistance and how can we overcome them? What role does the tumor microenvironment play? What model system is most appropriate for preclinical studies? What about combination therapy? How do you evaluate the utility of a novel biomarker candidate? Are there high throughput assays available to expedite the testing of drug or biomarker candidates? These are but a few of the issues that need to be resolved before we can cure cancer.

Did you know that Bio-Techne is comprised of industry leading brands including R&D Systems, Novus Biologicals, Tocris Bioscience, ProteinSimple, and Advanced Cell Diagnostics (ACD)? Together, we provide world class reagents, instruments, and technical support to drive your Cancer Immunotherapy Research. Click on the large bubbles to learn more!